Tao Wu, PhDBaylor College of Medicine2020 Scientific Scholar Award Targeting Epigenetic Landscape Reprogramming to Combat Drug-resistance in Ovarian Cancer Despite major improvements in therapeutic approaches to ovarian cancer, the ability of tumors to develop resistance to anti-cancer drugs remains the major challenge in achieving longer-lasting remission. One of the ways drug resistance is thought to […]
Read More
Melissa Fishel, PhDIndiana University School of Medicine Enhancement of ovarian cancer to chemotherapeutics agents, cisplatin and TMZ, using small molecules, BG and MX With the exception of a small percentage of patients presenting with stage IA/IB ovarian cancer, surgery along is inadequate treatment. However, virtually all patients who die from ovarian cancer have intrinsic or […]
Read More
Jason Wilken, PhD, BSYale University Overcoming Primary Herceptin Resistance in Ovarian Cancer Herceptin, a therapeutic antibody that targets ErbB2 and has a well-tolerated safety profile has proven exceptionally useful as a treatment for ErbB2+ breast cancer patients. Surprisingly, Herceptin has proven to be ineffective as a treatment option for ovarian cancer. Dr. Wilken, with the […]
Read More
Jean-Bernard Lazaro, PhDDana-Farber Cancer Institute Targeting DNA repair genes and the nucleolar proteome to increase cisplatin sensitivity in ovarian cancer Patients with ovarian cancer who are treated with cisplatin often develop resistance to the drug, as cisplatin acts by damaging cellular DNA, which in turn induces apoptosis. Repair of cisplatin-induced DNA damage by a few […]
Read More
Elizabeth Poole, PhDBrigham and Women’s Hospital2015 Skacel Family Scholar Medication use and ovarian cancer survival Although factors that contribute to ovarian cancer risk prior to diagnosis are currently being teased apart, factors which contribute to survival after a diagnosis of ovarian cancer have not yet been well studied. Dr. Poole’s project will develop the Nurses’ […]
Read More
Benjamin Izar, MD, PhDDana-Farber Cancer Institute Single-cell transcriptome analysis of treatment-resistant ovarian cancer and new strategies for drug discovery Dr. Izar will be studying in fine detail the molecular changes that take place from the time that ovarian cancer cells respond to platinum chemotherapy to when they become resistant. He will employ an innovative genetic […]
Read More
Elizabeth Harmon Stover, MD, PhDDana-Farber Cancer Institute Genomic analysis of plasma cell-free tumor DNA to evaluate clinical mechanisms of drug resistance in ovarian cancer Many ovarian cancers are able to resist drug treatment and therefore recur after months or years, posing a major challenge for clinicians and researchers. Currently research of resistant tumors is limited […]
Read More
Yaara Oren, Ph.DBroad InstituteCambridge, MA, United States Project: Using a novel single-cell lineage tracing technique to uncover the mechanisms driving ovarian cancer recurrence Research Area: Cancer Biology, Chemotherapy Resistance Summary:Despite a good initial response to chemotherapy, ovarian cancer comes back in the majority of patients and leads to death within 5 years of diagnosis. When the cancer […]
Read More
Erin George, MDUniversity of Pennsylvania2019 Lynda’s Fund Scholar Award Strategies to optimize drug tolerability without compromising efficacy Most women with ovarian cancer present with advanced stage disease. Large surgeries and toxic chemotherapies are the mainstay of treatment and, despite advances in medicine, most ovarian cancers return. Every tumor is unique in its biology, allowing for […]
Read More
Fang-Tsyr Lin, MD, PhDUniversity of Alabama at Birmingham Role of TRIP6 in Ovarian Cancer Progression TRIP6 is a novel molecule that helps make cancer cells immortal, thus allowing cancer to grow uncontrolled. This study will determine if silencing TRIP6 can increase the effectiveness of chemotherapy.
Read More